Faten Merhi

Faten Merhi

Auto-generated profile, based on publicly available information

Faten Merhi

Research Laboratory of Microbiology (RLM), Department of Life and Earth Sciences, Faculty of Sciences I, Lebanese University, Hadat Campus, P.O. Box 6573/14 Beirut, Lebanon

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2021 in Cells
Verified
Journal Article
Open access
PDF file
FMFaten Merhi
Faten Merhi
KVKarla Alvarez Valadez
Karla Alvarez Valadez
JTJENIFER TREPIANA
JENIFER TREPIANA
CLClaire Lescoat
Claire Lescoat
AGAlexis Groppi
Alexis Groppi
MMMojgan Djavahery Mergny
Mojgan Djavahery Mergny
Calcium ions (Ca2+) play important and diverse roles in the regulation of autophagy, cell death and differentiation. Here, we investigated the impact of Ca2+ in regulating acute promyelocytic leukemia (APL) cell fate in response to the anti-cancer agent all-trans retinoic acid (ATRA). We observed that ATRA promotes calcium entry through store-operated calcium (SOC) channels into acute promyelocytic leukemia (APL) cells. This response is associated with changes in the expression profiles of ORAI1 and STIM1, two proteins involved in SOC channels activation, as well as with a significant upregulation of several key proteins associated to calcium signaling. Moreover, ATRA treatment of APL cells led to a significant activation of calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) and its downstream effector AMP-activated protein kinase (AMPK), linking Ca2+ signaling to autophagy. Pharmacological inhibition of SOC channels and CAMKK2 enhanced ATRA-induced cell differentiation and death. Altogether, our results unravel an ATRA-elicited signaling pathway that involves SOC channels/CAMKK2 activation, induction of autophagy, inhibition of cellular differentiation and suppression of cell death. We suggest that SOC channels and CAMKK2 may constitute novel drug targets for potentiating the anti-cancer effect of ATRA in APL patients.

6 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
FMFaten Merhi
Faten Merhi
DDDaniel Dominique Dauzonne
Daniel Dominique Dauzonne
Brigitte BauvoisBrigitte Bauvois
Brigitte Bauvois
Bioactive natural products (NPs) may play a critical role in cancer progression by targeting nucleic acids and a wide array of proteins, including enzymes. Furthermore, a large number of derivatives (NPDs), including semi-synthetic products and pharmacophores from NPs, have been developed to enhance the solubility and stability of NPs. Acute myeloid leukemia (AML) is a poor-prognosis hematologic malignancy characterized by the clonal accumulation in the blood and bone marrow of myeloid progenitors with high proliferative capacity, survival and propagation abilities. A number of potential pathways and targets have been identified for development in AML, and include, but are not limited to, Fms-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenases resulting from genetic mutations, BCL2 family members, various signaling kinases and histone deacetylases, as well as tumor-associated antigens (such as CD13, CD33, P-gp). By targeting nucleic acids, FLT3 or CD33, several FDA-approved NPs and NPDs (i.e., cytarabine, anthracyclines, midostaurin, melphalan and calicheamicin linked to anti-CD33) are the major agents of upfront treatment of AML. However, the effective treatment of the disease remains challenging, in part due to the heterogeneity of the disease but also to the involvement of the bone marrow microenvironment and the immune system in favoring leukemic stem cell persistence. This review summarizes the current state of the art, and provides a summary of selected NPs/NPDs which are either entering or have been investigated in preclinical and clinical trials, alone or in combination with current chemotherapy. With multifaceted actions, these biomolecules may target all hallmarks of AML, including multidrug resistance and deregulated metabolism.

27 July 2022 in Food Science & Nutrition
Verified
Journal Article
Open access
AAAbdelkarim Arfa
Abdelkarim Arfa
MBMondher Boulaaba
Mondher Boulaaba
FMFaten Merhi
Faten Merhi
Brigitte BauvoisBrigitte Bauvois
Brigitte Bauvois
AIArnault Ingrid
Arnault Ingrid
HNHanen Najjaa
Hanen Najjaa
Epidemiologic studies keep up the proposition that Allium vegetables can lower the risk of cancers. Acute myeloid leukemia (AML) cells exhibit high proliferative potency and have a reduced capacity of undergoing apoptosis and maturation. The beneficial effects of Allium seem related to the organosulfur products generated upon processing of these species. For this purpose, the aim of this study was to test Allium roseum fresh (FAE), crude (CAE) and dried (DAE) aqueous extracts for activity against the human acute leukemia cell line (U937). As assessed by flow cytometry, inhibited cell proliferation was in a dose-dependent manner. Firstly, study showed that cell growth was inhibited with 20 mg/mL using FAE and CAE (60% and 73% respectively). Secondly, our experiments clearly indicate that all A. roseum extracts do not induce cell apoptosis. This was confirmed by the soft binding of Annexin V to phosphatidylserine. Finally, the high expression of macrophage's marker CD11 associated with adequate morphological changes proves clearly the differentiation aspect produced by A. roseum extract. Taken together, these data suggest that A. roseum could be a promising candidate for the alternative medicine in the field of cancer therapy.

4 September 2026 in Frontiers in Bioscience-Elite
Verified
Journal Article
Open access
PDF file
FMFaten Merhi
Faten Merhi
RBRana Barakat
Rana Barakat
NBNeressa Badr
Neressa Badr
NANour Akil
Nour Akil
ZAZahraa Allow
Zahraa Allow
ACAli Chokr
Ali Chokr
Background: This study aimed to investigate the antibacterial and antibiofilm activities of Trifolium purpureum against Escherichia coli. Methods: T. purpureum Loisel. was collected from the mountains of western Lebanon. The plant parts were then extracted by maceration in 70% ethanol and water. The plant fractions were screened for secondary metabolite classes. The antibacterial activity of the extracts was determined using the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). Antibiofilm activity was assessed using a colorimetric method, and the effects of T. purpureum extracts on the expression of genes involved in biofilm formation in E. coli were assessed by real-time quantitative polymerase chain reaction (qPCR). Results: Coumarins, tannins, volatile oils, and phenols were absent in T. purpureum; resins were detected only in the flowers, alkaloids were detected in all plant parts except the stems, and saponins, terpenoids, and flavonoids were found in all plant parts. Regarding antibacterial activity, although all extracts had measurable MIC values, only the whole-plant water extract exhibited a bactericidal effect. Furthermore, the water and ethanol extracts exhibited variable biofilm-prevention activity, with minimum biofilm prevention concentration (MBPC) values ranging from 30 to 68.9 mg/mL. Biofilm eradication activity also varied, with minimum biofilm eradication concentration (MBEC) values ranging from 0.13 to 49.65 mg/mL corresponding to 47.3–66.8% eradication. Finally, the whole-plant water extract suppressed the expression of fimA, fimH, and flu in both planktonic cells and cells within established E. coli biofilms. Conclusions: Our results demonstrate that T. purpureum is rich in secondary metabolites and has notable antibacterial and antibiofilm potential against E. coli, especially at the molecular level. These findings suggest that T. purpureum may be a promising candidate for use as an alternative antibacterial and antibiofilm agent.